Videos
Press Releases
27 Jun 2022
PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
29 Jun 2021
PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
4 Jun 2021
PRESS RELEASE: Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
Latest Newsletters
News
5 Aug 2022
EORTC Completes Patient Recruitment to Study of Treatment for unresectable or metastatic melanoma
27 Jul 2022
In Memoriam: Dr Martin Charles Mihm
26 Jul 2022
The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)
22 Jun 2022
Long-term follow-up of chemoradiotherapy treatment in glioma patients shows significantly increased survival
11 Jun 2022
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older patients with acute myeloid leukemia
24 May 2022
Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma
10 May 2022
Results of radiotherapy quality assurance in the PEACE-1 trial show high adherence to protocol
13 Apr 2022
EORTC presents new precision medicine research results at AACR 2022
1 Apr 2022
Joining forces to optimise cancer treatments in clinical practice: EMA & EORTC launch Cancer Medicines Forum with academia
